服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. The SARS-CoV-2 variant B1.617.2, also known as Delta variant, was first identified in India in the summer of 2020. This variant has deletion E156/F157 and mutations in the Spike protein (T19R, G142D, R158G, L452R, T478K, D614G, P681R) that may lead to higher transmissibility and infectivity. 产品介绍 The Spike S1 (B.1.617.2; Delta Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 (B.1.617.2; Delta Variant) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Variant B.1.618 was originally discovered in India. It contains mutations E484K and D614G; as well as deletion 145/146YH. 产品介绍 The Spike S1 (B.1.618 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.618) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Variant B.1.617, was originally discovered in India. This variant was the precursor to the B.1.617.1 (Kappa) variant and the B.1.617.2 (Delta) variant. It contains mutations L452R, E484Q, D614G and P681R. 产品介绍 The Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Variant B.1.351, also known as the Beta variant, was originally discovered in South Africa. It contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and D614G. 产品介绍 The Spike S1 (B.1.351; Beta Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.351) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pyruvate dehydrogenase (PDH) complex is a mitochondrial complex that converts pyruvate to acetyl-CoA. It is a primary regulator of glucose metabolism by providing the link between glycolysis and the tricarboxylic acid cycle. The enzymatic activity of PDH is regulated by a phosphorylation/dephosphorylation cycle, in which phosphorylation results in inactivation of PDH. PDK3 inhibits the PDH complex by phosphorylation of the E1 alpha subunit. PDK3 participates in the metabolic switch of cancer cells; although its significance in tumor malignancy is unknown. PDK3 has been implicated in drug resistance following the treatment of leukemia or colon cancer. 产品介绍 The PDK3 Kinase Assay Kit is designed to measure PDK3 activity for screening and profiling applications using ADP-Glo® as a detection reagent. The signal is measured using a luminometer or a microplate reader capable of reading chemiluminescence.
询价背景介绍 CD38, a differentiation antigen of B lymphocytes, is a type II integral membrane protein. It is also known as ADP-ribosyl cyclase and nicotinamide adenine dinucleotide (NAD+) glycohydrolase. Through its production of cyclic ADP-ribose, CD38 modulates calcium-mediated signal transduction in various cells, including pancreatic b cells, where it regulates insulin secretion. CD38 is a prognostic biomarker for acute B lymphoblastic leukemia, and anti-CD38 antibodies are in clinical trials as therapeutics for multiple myeloma. 产品介绍 The CD38 (Mouse) Inhibitor Screening Assay Kit (Cyclase Activity) is designed to measure the cyclase activity of CD38 (mouse) for screening and profiling applications. The CD38 assay kit comes in a convenient 96-well format, with purified recombinant CD38 enzyme, its substrate nicotinamide guanine dinucleotide (NGD+), and CD38 assay buffer for 100 enzyme reactions. In addition, the kit includes the CD38 inhibitor quercetin for use as an inhibitor control.
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. A variant called P.1, also known as Gamma variant, was first identified in Brazil in the summer of 2020. This variant has many mutations in the Spike protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y) that may lead to higher transmissibility and infectivity. 产品介绍 The Spike S1 (P.1; Gamma Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (P.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa variant) was identified in India in the spring of 2021. This variant has a number of mutations in the Spike protein (G142D, E154K, L452R, E484Q, D614G, P681R) that may allow the virus to spread more easily and quickly than other variants. 产品介绍 The Spike S1 (B.1.617.1; Kappa Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价背景介绍 The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. SARS-CoV-2 (B.1.1.7), also known as Alpha variant, was first identified in the United Kingdom in the summer of 2020. This variant contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y in the Spike protein that may lead to higher transmissibility and infectivity. 产品介绍 The Spike S1 (B.1.1.7; Alpha Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 (B.1.1.7; Alpha Variant) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
询价
